13F Holdings
中文EN

KYMR Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815442 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY133.8%
TTM net income YoY-18.4%
TTM EPS YoY-1.1%
Revenue 3-yr CAGR29.7%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-396.0%
Net margin-341.8%
FCF margin-282.6%
EBITDA margin-388.9%

Returns

ROE-27.3%
ROA-24.4%
ROIC (approx.)-30.8%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets8.6%
Debt / equity0.00x
Current ratio11.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$39.21M$47.07M$78.59M$46.83M$72.83M
Cost of revenue$39.21M$47.07M$78.59M$46.83M—
Gross profit$0$0$0$0—
R&D expense$316.57M$240.25M$189.08M$164.25M$137.02M
SG&A expense$68.19M$63.53M$55.04M$43.83M$36.34M
Operating income-$349.40M-$261.63M-$165.53M-$161.26M-$100.53M
Pretax income-$311.35M————
Income tax$0——$0$0
Net income-$311.35M-$223.86M-$146.96M-$154.81M-$100.22M
EBITDA-$341.09M-$254.26M-$161.97M-$158.28M-$98.13M
EPS (basic)-3.69-2.98-2.52-2.87-2.09
EPS (diluted)-3.69-2.98-2.52-2.87-2.09
Weighted avg. shares (diluted)84.49M75.04M58.37M53.93M47.99M
Balance sheet
Cash & equivalents$357.01M$120.26M$109.97M$68.39M$47.98M
Short-term investments$491.26M$368.49M$264.92M$338.77M$394.44M
Receivables$0$0$15.00M$0—
Current assets$871.21M$510.27M$405.32M$419.42M$451.27M
PP&E, net$43.17M$50.46M$48.13M$13.33M$11.88M
Total assets$1.74B$978.03M$575.76M$603.13M$605.90M
Current liabilities$83.21M$67.77M$85.69M$71.34M$92.54M
Total liabilities$163.15M$142.42M$180.79M$112.98M$146.27M
Shareholders' equity$1.58B$835.62M$394.97M$490.15M$459.64M
Shares outstanding81.32M64.89M55.59M55.04M51.54M
Cash flow statement
Operating cash flow-$232.89M-$194.50M-$102.83M-$153.09M-$128.95M
Capital expenditure$1.45M$12.84M$34.48M$2.84M$1.60M
Free cash flow-$234.34M-$207.34M-$137.31M-$155.92M-$130.54M
Investing cash flow-$521.06M-$404.08M$139.89M$20.52M-$99.83M
Financing cash flow$990.71M$608.85M$4.19M$153.00M$250.28M
Depreciation & amortization$8.31M$7.37M$3.56M$2.98M$2.40M
Stock-based compensation$59.90M$55.01M$43.12M$35.48M$24.97M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.